Aug 7 |
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
|
Aug 6 |
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
|
Jul 12 |
Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation
|
Jun 20 |
Compass Therapeutics: Pointing Right At Some Tough Cancers
|
May 30 |
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
May 28 |
Compass Therapeutics names Thomas Schuetz as CEO
|
May 28 |
Compass Therapeutics Announces CEO Transition
|